Mumbai, July 24 -- Profit before tax (PBT) stood at Rs 1,905 crore in Q1 FY26, up 1.2% YoY

EBITDA for the quarter stood at Rs 2,278.4 crore, up 5.49% YoY.

In its global generics business, North America contributed Rs 3,412.3 crore in revenue, a 11% year-on-year decline. Revenue from Europe surged 142% to Rs 1,274.4 crore, The India business generated revenue of Rs 1,471.1 crore, registering an 11% YoY.

Revenue from Pharmaceutical Services and Active Ingredients (PSAI) came in at Rs 818.1 crore, a 7% YoY increase.

Co-Chairman & MD, G V Prasad, said: "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio...